Tech Company Financing Transactions
Vedanta Biosciences Funding Round
Vedanta Biosciences closed a $68 million Series D funding round on 7/22/2021. Backers included Magnetar Capital Return, Fosun Pharma and Health for Life Capital Fund.
Transaction Overview
Company Name
Announced On
7/22/2021
Transaction Type
Venture Equity
Amount
$68,000,000
Round
Series D
Investors
Proceeds Purpose
The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
19 Blackstone St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/22/2021: Dwolla venture capital transaction
Next: 7/22/2021: Simfoni venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs